A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia.
Pau MontesinosVamsi KotaJoseph BrandweinPierre BoussetRebecca J BennerErik VandendriesYing ChenMary Frances McMullinPublished in: Cancer chemotherapy and pharmacology (2023)
Clinicaltrials.gov ID: NCT03727750 (November 1, 2018).